Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges

Drugs in Context
Shinichi MakitaKensei Tobinai

Abstract

B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is considered the most promising and effective therapy to overcome chemorefractory B-cell NHL. Based on the promising results obtained from pivotal trials, the US Food and Drug Administration and European Medicines Agency approved anti-CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma. Nonetheless, there remain several controversial issues and problems awaiting solutions, including optimal management of toxicities, overcoming relapsed/refractory disease after CAR T-cell therapy, and improving CAR-T manufacturing platform. Definite unmet medical needs among patients with chemorefractory B-cell NHL still exist. CAR T-cell therapy might be a game changer that can defeat chemorefractory B-cell NHL, and further clinical development is warranted. In this review, we summarize the recent clinical developments, clinical implications, and perspectives of CAR T-cell therapy, focusing on B-cell NHL.

Citations

Mar 21, 2020·Medicine·Qi WangYisheng Tao
Jul 28, 2020·Expert Opinion on Drug Safety·Shinichi MakitaKensei Tobinai
Sep 4, 2020·Clinical and Translational Science·Peter N MorcosChi-Chung Li
Apr 28, 2021·Journal of Hematology & Oncology·Krish Patel, John M Pagel
Oct 28, 2019·Clinical Lymphoma, Myeloma & Leukemia·Avyakta Kallam, Julie M Vose
Jan 18, 2020·Clinical Lymphoma, Myeloma & Leukemia·Swetha KambhampatiCharalambos Andreadis
Sep 17, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shwetha H ManjunathIma Paydar

❮ Previous
Next ❯

Methods Mentioned

BETA
leukapheresis
biopsy

Clinical Trials Mentioned

NCT02445248
NCT02348216
NCT02650999
NCT03448393
NCT02746952
NCT03570892
NCT03575351

Software Mentioned

CAR
JULIET
CliniMACS Prodigy

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.